Q1FY19 Result: Aksharchem PAT increases to Rs. 7.55 crore
Q1FY19 Result: Aksharchem PAT increases to Rs. 7.55 crore

Q1FY19 Result: Aksharchem PAT increases to Rs. 7.55 crore

Nidhi Jani Article rating: 5.0

The company’s consolidated revenue for the quarter came in at Rs. 75.46 crore as against Rs. 63.74 crore in the corresponding quarter last year, registering 18.4 per cent yoy increase.

MF Update: MF AUM increased marginally in July 2018
MF Update: MF AUM increased marginally in July 2018

MF Update: MF AUM increased marginally in July 2018

Shashikant Singh Article rating: 5.0

Equity funds continued to increase their presence in the domestic MF asset under management. This is despite a declining trend in the net inflows to the equity funds.

TVS Motors reports steady results
TVS Motors reports steady results

TVS Motors reports steady results

Rohan Takalkar Article rating: No rating

TVS Motors posted steady results for the quarter with strong revenue growth and EBITDA margin expansion.

BEL bags Rs. 9,200 crore missile order
BEL bags Rs. 9,200 crore missile order

BEL bags Rs. 9,200 crore missile order

Gayathri Udyawar Article rating: 3.0

State-owned aerospace and defence company, BEL will supply and services seven Long-range Surface-to-air Missile systems for MDL and GRSE.

IPO Analysis: Credit access Grameen ltd
IPO Analysis: Credit access Grameen ltd

IPO Analysis: Credit access Grameen ltd

Rohan Takalkar Article rating: 3.5

The IPO of Creditaccess Gramin Limited opens for subscription from August 8 to August 10, 2018. This IPO consists of fresh equity issue worth Rs. 630 crore (1,49,28,910 shares) and offer for sale (OFS) of 1,18,76,485 shares by existing stakeholders. Post issue, promoter and promoter group’s holding will reduce to 80.3% and non-promoter shareholding will increase to 19.7% from 1.1%. The face value is Rs 10 per equity share. The minimum lot size is of 35 shares and the issue price band is Rs. 418-422 per equity share. Post allotment, the company will get listed on both BSE and NSE.

USFDA to review allergic rhinitis drug of Glenmark Pharma
USFDA to review allergic rhinitis drug of Glenmark Pharma

USFDA to review allergic rhinitis drug of Glenmark Pharma

Sanket Dewarkar Article rating: 2.5

U.S. Food and Drug Administration (FDA) has accepted for review the company’s New Drug Application for Ryaltris, an investigational fixed-dose combination nasal spray for seasonal allergic rhinitis (SAR) in patients 12 years of age and older.

Genesys International signs MoU with Wipro for Autonomous Vehicles
Genesys International signs MoU with Wipro for Autonomous Vehicles

Genesys International signs MoU with Wipro for Autonomous Vehicles

Nidhi Jani Article rating: 5.0

As per the MoU, Genesys will develop HD Mapping and content by using its core strength and skills. Whereas, Wipro will develop the directional and controller technology for the autonomous system and smart mobility companies.

Pondy Oxides spikes 8 per cent post Q1FY19 numbers
Pondy Oxides spikes 8 per cent post Q1FY19 numbers

Pondy Oxides spikes 8 per cent post Q1FY19 numbers

Nidhi Jani Article rating: 5.0

EBITDA for the quarter rose by 30.4 per cent yoy to Rs. 15.51 crore as against Rs. 11.89 crore in the corresponding quarter last year, with a corresponding margin expansion of 125 bps.

RSS
First32483249325032513253325532563257Last

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR